Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature

References

• Departments of Labor, Health and Human Services, and Education. Senate Report 109–103. 109th Congress, 1st Session 2006.
   Google Scholar
• Melnikova I. Anaemia therapies. Nat Rev Drug Discov 2006; 5: 627–628
   PubMed Web of Science ®Google Scholar
• McClellan WM, Jurkovitz C, Abramson J. The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease. EurJ Clin Invest 2005; 35(Suppl 3)58–65
   PubMedGoogle Scholar
• McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501–1510
   PubMed Web of Science ®Google Scholar
• Jungers PY, Robino C, Choukroun G, et al. Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients. Nephrol Dial Transplant 2002; 17: 1621–1627
   PubMed Web of Science ®Google Scholar
• Obrador GT, Pereira BJ. Anaemia of chronic kidney disease: an under-recognized and under-treated problem. Nephrol Dial Transplant 2002; 17(Suppl 11)44–46
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Chen SC, Whaley-Connell AT, et al. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008; 51(4 Suppl 2)S46–55
   PubMed Web of Science ®Google Scholar
• Lorber DL, Provenzano R, McClellan W. Prevalence and treatment of anemia with once-weekly epoetin alfa in patients with diabetes and chronic kidney disease. Endocr Pract 2006; 12: 506–513
   PubMedGoogle Scholar
• Ershler WB, Chen K, Reyes EB, et al. Economic burden of patients with anemia in selected diseases. Value Health 2005; 8: 629–638
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Duh MS, Buteau S, et al. Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease. J Am Soc Nephrol 2006; 17: 3497-3502
   Web of Science ®Google Scholar
• KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471–530.
   Google Scholar
• Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. ClinJ Am Soc Nephrol 2009; 4: 33–38
   PubMed Web of Science ®Google Scholar
• Wish J, Schulman K, Law A, et al. Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: a retrospective claims database analysis. Kidney Blood Press Res 2009; 32: 110–118
   PubMed Web of Science ®Google Scholar
• Rasu RS, Manley HJ, Crawford T, et al. Undertreatment of anemia in patients with chronic kidney disease in the United States: analysis of national outpatient survey data. Clin Ther 2007; 29: 1524–1534
   PubMed Web of Science ®Google Scholar
• London R, Solis A, Goldberg GA, et al. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. AmJ Kidney Dis 2002; 40: 539–548
   PubMed Web of Science ®Google Scholar
• Kimmel PL, Greer JW, Milam RA, et al. Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998. Semin Nephrol 2000; 20: 335–344
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019–2032
   PubMed Web of Science ®Google Scholar
• Maddux FW, Shetty S, del Aguila MA, et al. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. Ann Pharmacother 2007; 41: 1761–1769
   PubMed Web of Science ®Google Scholar
• Moyneur E, Bookhart BK, Mody SH, et al. The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective. Dis Manag 2008; 11: 49–58
   PubMedGoogle Scholar
• Papatheofanis F, Bookhart BK, Muser E, et al. An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease. J Occup Environ Med 2008; 50: 584–589
   PubMed Web of Science ®Google Scholar
• Perkins R, Olson S, et al. Impact of an anemia clinic on emergency room visits and hospitalizations in patients with anemia of CKD pre-dialysis. Nephrology Nursing 2007; 34: 167–182
   Google Scholar
• Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004; 61: 392–405
   PubMed Web of Science ®Google Scholar
• Alexander M, Kewalramani R, Agodoa I, et al. Association of anemia correction with health related quality of life in patients not on dialysis. Curr Med Res Opin 2007; 23: 2997–3008
   PubMed Web of Science ®Google Scholar
• Cella D, Yount S, Sorensen M, et al. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 811–819
   PubMed Web of Science ®Google Scholar
• Revicki DA. Relationship between health utility and psychometric health status measures. Med Care 1992; 30(5 Suppl)MS274–282
   PubMed Web of Science ®Google Scholar
• Muirhead N, Cattran DC, Zaltzman J, et al. Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol 1994; 5: 1216–1222
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–2098
   PubMed Web of Science ®Google Scholar
• Abu-Alfa AK, Sloan L, Charytan C, et al. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin 2008; 24: 1091–1100
   PubMed Web of Science ®Google Scholar
• Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006; 26: 445–454
   PubMed Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071–2084
   PubMed Web of Science ®Google Scholar
• Benz R, Schmidt R, Kelly K, et al. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 215–221
   PubMed Web of Science ®Google Scholar
• Provenzano R, Bhaduri S, Singh AK. PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005; 64: 113–123
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Vekeman F, Sarokhan B, et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin 2006; 22: 1929–1937
   PubMed Web of Science ®Google Scholar
• Revicki DA, Brown R, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25: 548–554
   PubMed Web of Science ®Google Scholar
• Kleinman KS, Schweitzer SU, Perdue ST, et al. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis 1989; 14: 486–495
   PubMed Web of Science ®Google Scholar
• Sobrero A, Puglisi F, Guglielmi A, et al. Fatigue: a main component of anemia symptomatology. Semin Oncol 2001; 28(2 Suppl 8)15–18
   PubMed Web of Science ®Google Scholar
• Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 2009; 75: 15–24
   PubMed Web of Science ®Google Scholar
• Gandra SR, Finkelstein FO, Bennett AV, et al. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. AmJ Kidney Dis 2010; 55: 519–534
   PubMed Web of Science ®Google Scholar
• Unger EF, Thompson AM, Blank MJ, et al. Erythropoiesis-stimulating agents – time for a reevaluation. N Engl J Med 2010; 362: 189–192
   PubMed Web of Science ®Google Scholar
• Odden MC, Whooley MA, Shlipak MG. Association of chronic kidney disease and anaemia with physical capacity: the heart and soul study. JAm Soc Nephrol 2004; 15: 2908–2915
   PubMed Web of Science ®Google Scholar
• Lindgren C. New survey provides insight into CKD, exhaustion, anaemia. Nephrol News Issues 2003; 17: 29–31
   Google Scholar
• Ware JE, Kosinski M, Dewey JE. How to score Version Two of the SF-36 Health Survey. Lincoln, RI: Quality Metric, Incorporated, 2000.
   Google Scholar